ALEXION PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1992-01-01

Employees: 3.8K

Market Cap: -

Website: http://www.alexion.com

Clinical Trials

aHUS Observational Long Term Follow-Up

Terminated

Conditions: Atypical Hemolytic Uremic Syndrome

First Posted Date: 2012-01-31

Last Posted Date: 2017-02-24

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 94

Registration Number: NCT01522170

Locations: 🇺🇸
Emory Healthcare - Children's Center, Atlanta, Georgia, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dunwoody Pediatrics & Children's Healthcare of Atlanta, Dunwoody, Georgia, United States

and more 52 locations

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Recruiting

Conditions: Atypical Hemolytic-Uremic Syndrome

First Posted Date: 2012-01-31

Last Posted Date: 2024-11-15

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 3000

Registration Number: NCT01522183

Locations: 🇬🇧
Clinical Trial Site, Wales, United Kingdom
🇪🇸
Clinical Trial Site 1, Barcelona, Spain
🇪🇸
Clinical Trial Site 2, Barcelona, Spain

and more 9 locations

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

Phase 2

Completed

Conditions: LAL-Deficiency
Cholesterol Ester Storage Disease (CESD)
Lysosomal Acid Lipase Deficiency

Interventions: Drug: sebelipase alfa

First Posted Date: 2011-12-08

Last Posted Date: 2018-07-20

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 8

Registration Number: NCT01488097

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALXN1007
Other: Placebo

First Posted Date: 2011-10-19

Last Posted Date: 2017-02-03

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 64

Registration Number: NCT01454986

Locations: 🇺🇸
PAREXEL Baltimore EPCU, Baltimore, Maryland, United States

A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

Completed

Conditions: Hypophosphatasia (HPP)

First Posted Date: 2011-08-17

Last Posted Date: 2019-04-01

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT01419028

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Indiana University school of medicine, Indianapolis, Indiana, United States
🇺🇸
Shriners Hospital for Children, Saint Louis, Missouri, United States

and more 9 locations

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Completed

Conditions: PNH
Paroxysmal Nocturnal Hemoglobinuria

First Posted Date: 2011-08-08

Last Posted Date: 2017-10-18

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 75

Registration Number: NCT01412047

Locations: 🇩🇪
Universitatsklinikum Essen, Essen, Germany
🇩🇪
Institut fur Klinische Transfusionmedizin und Immungenetick, Ulm, Germany
🇮🇹
Azienda Ospediliera Universitatia Careggi, Firenze, Italy

and more 4 locations

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

Phase 2

Completed

Conditions: Shiga-like Toxin-producing Escherichia Coli

First Posted Date: 2011-08-05

Last Posted Date: 2013-04-05

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 198

Registration Number: NCT01410916

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Phase 2

Terminated

Conditions: Antibody Mediated Rejection

Interventions: Drug: Eculizumab

First Posted Date: 2011-07-22

Last Posted Date: 2017-10-03

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 102

Registration Number: NCT01399593

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

First Posted Date: 2011-06-16

Last Posted Date: 2024-03-01

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 5950

Registration Number: NCT01374360

Locations: 🇺🇸
Contact the PNH Registry at Alexion Pharmaceuticals, Inc. for worldwide locations., Boston, Massachusetts, United States

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Phase 2

Completed

Conditions: Lysosomal Acid Lipase Deficiency
Wolman Disease

Interventions: Drug: Sebelipase alfa (SBC-102)

First Posted Date: 2011-06-13

Last Posted Date: 2019-01-30

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 9

Registration Number: NCT01371825

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy